Search Results
Your search for The ASCO Post staff matches 6856 pages
Showing 2851 - 2900
Anna Sureda, MD, PhD, on Large B-Cell Lymphoma: New Data on Axicabtagene Ciloleucel vs Standard of Care
Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabtagene ciloleucel was superior to second-line standard-of-care treatment in patients 65 years or...
Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy
Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 ...
Study Examines Effects of Advance Care Planning for Adolescents With Cancer
In a recently published study by Needle et al in JAMA Network Open, University of Minnesota researchers and colleagues say adolescents with cancer deserve a voice in medical decisions made for and about them. “Adolescents with cancer should be given the opportunity to participate in their own...
Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia
Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...
Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, 2022, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare...
Anthony S. Fauci, MD, to Step Down From Current Roles in December
Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), announced his intention to step down from his various roles in December 2022. He issued the following statement on August 22: I am announcing today that I will be stepping down from the positions...
Racial Trends in Advanced Cervical Cancer in the United States
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations
Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...
PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the...
Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...
Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?
Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...
T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
Pralsetinib Achieves Tissue-Agnostic Benefits for Patients With RET Fusion–Positive Cancers
The highly selective RET inhibitor pralsetinib was well tolerated and demonstrated robust, durable responses in patients with RET fusion–positive cancers regardless of tumor type, according to results from the international phase I/II ARROW trial. Results from the trial were published in Nature...
Study Reveals Potential Genomic Contributors to the Development of DLBCL
By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...
Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers
A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...
Molecular Map Reveals Insights Into the Genetic Drivers of CLL
A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy, which could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were...
Sugemalimab Found to Be a Safe and Effective Consolidation Therapy for Patients With Unresectable Stage III NSCLC
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to...
Higher Doses of CAR T-Cell Therapy May Improve Survival for Young Patients With B-Cell ALL
Young people with B-cell acute lymphoblastic leukemia (ALL) who received doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, at the higher end of the approved dosing range had significantly better survival rates at 1 year compared with those who received lower doses within...
Sexual Dysfunction Is Prevalent Among Women With Lung Cancer
Sexual dysfunction is highly prevalent in women with lung cancer, with most participants in a survey reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, presented at the International Association for the Study of Lung Cancer (IASLC) World...
Study Investigates Incidence, Timing, and Survival of Patients With Second Primary Lung Cancer
Using data from the National Lung Screening Trial (NLST), researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of patients with lung cancer and was as high as 8% among patients undergoing surgery for stage IA disease. The research was...
NELSON Trial Protocol May Be More Sensitive Than NLST, May Increase Benefits of Lung Cancer Screening
The protocol used to screen and detect lung cancer in the NELSON trial may be more sensitive than the protocol used in the National Lung Cancer Screening Trial (NLST), particularly for early-stage cancers, according to research reported by de Nijs et al at the International Association for the...
Perspective Article Explores Implications of Supreme Court Abortion Ruling on Pregnant Women With Cancer
The repercussions of overturning Roe v Wade—and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother—are potentially catastrophic for a subset of women who face a life-threating diagnosis of pregnancy-associated cancers. In a...
Informed Consent Forms for Lung Cancer Clinical Trials May Be a Barrier to Informed Participation
Informed consent forms can be overwhelming for patients—they are written at a level that is too high for many patients, possibly impeding true informed consent, according to a report given by King-Kallimanis et al at the International Association for the Study of Lung Cancer (IASLC) 2022 World...
Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study
Researchers from Japan recently reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1–positive unresectable locally advanced non–small cell lung cancer (NSCLC) without chemotherapy met its primary endpoint with...
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2-Mutant NSCLC
On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for adult patients with unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations, as detected by an...
FDA Approves Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutations
On August 10, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an ...
Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer
Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022 (Abstract...
Disparities in the Diagnosis of Lung Cancer Among Younger vs Older Adults
Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening. ...
FDA Approves Ventana MMR RxDx Panel to Identify Patients With dMMR Solid Tumors and pMMR Endometrial Cancer Eligible for Treatment With Pembrolizumab
On August 11, Roche announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for the Ventana MMR RxDx Panel. The Ventana MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA ...
Study Finds AYA Leukemia Survivors Have Higher 10-Year Mortality Rates Than the General Population
Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...
Dana-Farber’s Irene Ghobrial, MD, Selected as William Dameshek Prize Winner
Irene Ghobrial, MD, Director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute, Boston, has received the William Dameshek Prize. This award is given annually by the American Society of Hematology (ASH) to an individual younger than age 50 who has made outstanding...
Jaye Gardiner, PhD, Receives the 2022 Eddie Méndez Award Honoring Underrepresented Scientists
Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, Philadelphia, is among 10 recipients of the 2022 Dr. Eddie Méndez Award. This honor recognizes underrepresented postdoctoral researchers across the United States who have demonstrated research expertise in cancer, infectious...
Radiologist Claudia Henschke, PhD, MD, of Icahn School of Medicine, Receives the 37th Annual Alton Ochsner Award
Ochsner Health has announced the recipient of the 37th Annual Alton Ochsner Award Relating Smoking and Disease: Claudia Henschke, PhD, MD. She is Director, Early Lung and Cardiac Action Program (ELCAP) and Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York. This...
Pat Morin, PhD, Appointed Deputy Scientific Director of the Ludwig Institute for Cancer Research
Ludwig Cancer Research recently announced the appointment of Pat Morin, PhD, as Deputy Scientific Director of its international nonprofit organization, the Ludwig Institute for Cancer Research. Dr. Morin joins Ludwig from the University of Pennsylvania, where he has served as Executive Director for ...
An Oncology Nurse Becomes a Cancer Survivor
In 2016, Theresa Brown, RN, wrote The Shift: One Nurse, Twelve Hours, Four Patients’ Lives, a vivid real-time description of an oncology nurse’s standard 12-hour shift on a hospital cancer ward. It was an excellent book, which was reviewed on these pages and highly recommended for readers of The...
Robert Uzzo, MD, MBA, FACS, Appointed President and CEO of Fox Chase Cancer Center
Robert Uzzo, MD, MBA, FACS, has been named President and Chief Executive Officer (CEO) of Fox Chase Cancer Center, Philadelphia. In addition, Dr. Uzzo will assume the roles of Executive Vice President, Cancer Services for Temple University Health System, and Senior Associate Dean, Clinical Cancer...
Donna Hansel, MD, PhD, to Join MD Anderson as Division Head of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center recently announced that Donna Hansel, MD, PhD, has been named Division Head of Pathology and Laboratory Medicine. Dr. Hansel will lead a team of 650, including more than 130 clinical and research faculty, across 4 departments that serve as a bridge...
Howard Sandler, MD, FASTRO, Voted President-Elect of ASTRO Along With Other New Officers
The members of the American Society for Radiation Oncology (ASTRO) elected seven new officers to the society’s Board of Directors, including Howard Sandler, MD, FASTRO, as President-Elect; Michael Kuettel, MD, PhD, MBA, FASTRO, as Secretary/Treasurer-Elect; Iris C. Gibbs, MD, FASTRO, and Curtiland...
Selwyn M. Vickers, MD, FACS, Named President and CEO of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) recently announced that Selwyn M. Vickers, MD, FACS, a pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has been selected to serve as its next President and Chief Executive...
Increased Utilization of SBRT Has Decreased Treatment Disparities for Early-Stage NSCLC
The use of stereotactic body radiotherapy (SBRT) for patients with non–small cell lung cancer (NSCLC) can reduce treatment disparities between White and Black patients, according to research presented by Ganesh et al at the International Association for the Study of Lung Cancer (IASLC) World...
Study Finds Adding Tremelimumab and Durvalumab to Chemotherapy Improves Overall Survival in Metastatic NSCLC Regardless of KRAS/STK11/KEAP1 Mutations
Patients with metastatic non–small cell lung cancer (NSCLC) who received a combined therapy of tremelimumab, durvalumab, and chemotherapy experienced longer overall survival compared with those who received chemotherapy alone, regardless of STK11, KEAP1, or KRAS mutational status. These findings...
Kimberly Hoggatt Krumwiede, PhD, Named Dean of MD Anderson’s School of Health Professions
The University of Texas MD Anderson Cancer Center, Houston, has chosen Kimberly Hoggatt Krumwiede, PhD, as Dean of MD Anderson’s School of Health Professions. “Dr. Hoggatt Krumwiede exemplifies the qualities we sought to lead our School of Health Professions. She is a skilled and strategic leader...
Why Do Men Face a Higher Risk of Most Types of Cancer Than Women?
Rates of most types of cancer are higher in men than in women for reasons that are unclear. Results from a recent study published online by Jackson et al in the journal Cancer suggest that the cause may be underlying biological sex differences rather than behavioral differences related to smoking,...
FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
On August 5, 2022, the U.S. Food and Drug Administration approved darolutamide (Nubeqa) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer. The evaluation of efficacy was based on ARASENS (ClinicalTrials.gov identifier NCT02799602), a...
Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Evaluation of Fruquintinib for Metastatic Colorectal Cancer
The pivotal global phase III FRESCO-2 trial evaluating the investigational use of fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for the...
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu), an intravenous infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy targeted to patients with the...
Genetics May Predict Bladder Cancer Immunotherapy Response
Investigators have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy with immune checkpoint inhibitors. Their findings, published by You et al in the Journal of the National Cancer Institute, implicate DDR1- and...
Research Shows Poor Patient Comprehension of Terms Commonly Found in Electronic Health Information
When the 21st Century Cures Act went into effect in April 2021, health-care organizations began releasing electronic health information to patients immediately. An aim of the act is to reduce barriers to patients’ timely access to electronic health information, and previous research has shown that...
